MedTrace Logo

Pharmacotherapy Prescribing Pattern and the Adherence Level to Iron Chelation Therapy in Thalassemia

NCT06210139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2024-07-23

No results posted yet for this study

Summary

Thalassemias are a heterogeneous grouping of genetic disorders that result in dysfunctional Hb, reduced RBC life span leading to chronic anemia . Thalassemia is endemic in the Middle East. Iron chelation therapy (ICT) is one of treatment used however ICT is associated with patients adherence problem thus impacting its effectiveness .

Conditions

Sponsors & Collaborators

  • Reem Ali Shaker

    lead OTHER

Principal Investigators

  • Fadhil A Riziji, PhD · Kufa university/ faculty of pharmacy

Eligibility

Min Age
3 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2024-02-28
Completion
2024-02-28

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210139 on ClinicalTrials.gov